Form 4: Vaxart, Inc. (VXRT), Wheadon David E., transaction 06/16/2021

Summary

David E. Wheadon, a director of Vaxart, Inc., reports in this Form 4 a stock option (right to buy) for 65,700 shares of common stock at $6.54, dated 06/16/2021 and expiring 05/09/2031. A footnote states that the board of directors granted the option effective May 10, 2021, subject to stockholder approval of an amendment to the Vaxart, Inc. 2019 Equity Incentive Plan, which the stockholders approved on June 16, 2021. The shares vest annually over three years from April 21, 2021, the date of the grantee's appointment as a director. Margaret Echerd signed as Attorney-in-Fact for David Wheadon on 06/17/2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Wheadon David E. (Last) (First) (Middle) C/O VAXART, INC. 170 HARBOR WAY, SUITE 300 (Street) SOUTH SAN FRANCISCO CA 94080 (City) (State) (Zip) | Wheadon David E. | (Last) | (First) | (Middle) | C/O VAXART, INC. | 170 HARBOR WAY, SUITE 300 | SOUTH SAN FRANCISCO | CA | 94080 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Vaxart, Inc. [ VXRT ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) | X | Director | 10% Owner | Officer (give title below) | Other (specify below)
3. Date of Earliest Transaction
 (Month/Day/Year) 06/16/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Stock Option (right to buy) | $ 6.54 | 06/16/2021 (1) | A | 65,700 | (2) | 05/09/2031 | Common stock | 65,700 | $ 0 | 65,700 | D
Explanation of Responses:
1. The option was granted by the board of directors of Vaxart, Inc. effective on May 10, 2021, subject to stockholder approval of an amendment to the Vaxart, Inc. 2019 Equity Incentive Plan, under which the stock option was granted. Vaxart, Inc.'s stockholders approved the plan amendment on June 16, 2021.
2. The shares subject to this option shall vest annually over three years from the vesting commencement date of April 21, 2021, the date of the grantee's appointment as a director of Vaxart, Inc.
/s/ Margaret Echerd, Attorney-in-Fact for David Wheadon | 06/17/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_VXRT_4_filed2021-06-17_0001437749-21-015115.xml

Size

15,813 bytes

SHA-256

b9aa9f23b797e2ef17e98d3ff4fa2e57763421a01f179991724e92a36bca9c6e

Our copy

SEC_VXRT_4_filed2021-06-17_0001437749-21-015115.xml

Original

www.sec.gov